Pernix Therapeutics (PTX) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics Reports Third Quarter 2015 Financial Results
November 5, 2015 6:50 AM ESTRevenue Increases 54% Year-Over-Year
Company Reiterates Financial Guidance
MORRISTOWN, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015. Third Quarter and Recent Business Highlights:
Increased Treximet total prescriptions by 7% and new prescriptions by 13% versus the second quarter of 2015;Increased Silenor total prescriptions by 7%, and new prescriptions by 2% compared to the second quarter of... More